opens new tab have settled Acuitas' lawsuit demanding credit for inventions related to COVID-19 vaccines, according to a filing on Thursday in Virginia federal court. Acuitas sued CureVac last ...

A New Jersey court has said that Acuitas Therapeutics failed to plead a case or controversy in its suit against Genevant ...

In November 2023, Acuitas Therapeutics filed a lawsuit in Virginia federal court against CureVac, accusing it of failing to credit Acuitas on patents related to COVID-19 vaccines. Acuitas told the ...

Aldevron, a leading global manufacturer of DNA, RNA, and proteins used in cell and gene therapies and vaccine development, ...

The homes of University of Michigan regents have become the latest front for protesters demanding the university divest from ...

Shares of Mullen Automotive (NASDAQ:MULN) stock are in the spotlight after the electric vehicle (EV) company announced that it had entered into a letter of agreement (LOA) with Acuitas Capital in ...

The Hunter Laboratory at the University of Pennsylvania School of Veterinary Medicine, the Webby Lab at St. Jude, and Steven ...

View all of Acuitas’s mutual funds and start searching for your next investment. Below are pre-screened investment lists to kickstart the process. All lists can be further sorted by data points ...

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), with a price ...

Acuitas previously secured a separate license for the lipid nanoparticle technology used in Pfizer/BioNTech's COVID-19 vaccine. Acuitas said CureVac omitted its scientists from patent ...

This partnership will allow Aldevron to expand its capabilities in mRNA LNP encapsulation by incorporating Acuitas’ proprietary LNP encapsulation platform, increasing Aldevron’s services and ...